PR Newswire Clinical TrialsOriginal article
HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism
Data ReadoutpositiveEKOS Endovascular SystemPositive
AI Analysis
Summary
Boston Scientific's HI-PEITHO trial demonstrated that the EKOS Endovascular System combined with anticoagulation achieved statistically significant reduction in clinical event rates compared to anticoagulation alone for intermediate-risk acute pulmonary embolism treatment. Late-breaking findings were presented at ACC.26 and simultaneously published.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
HI-PEITHO trial demonstrated statistically significant reduction in clinical event rates for EKOS device plus anticoagulation vs. anticoagulation alone in intermediate-risk PE patients
Importance:7/10
Sentiment:
0.85
Clinical TrialMedical DevicePulmonary EmbolismLate Breaking DataACC Conference
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on March 28, 2026 2:38 PM